CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-17 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-11-17 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,300 | $51.73 | $171K | 154,102 |
| 2026-11-17 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −200 | $52.59 | $11K | 153,902 |
| 2026-11-17 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 9,386 | ||
| 2026-11-17 | Hessekiel Jeffrey Chief Legal & Admin Officer | Sale | −15,106 | $52.62 | $795K | 92,837 |
| 2026-11-16 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +7,500 | $10.60 | $80K | 286,044 |
| 2026-11-16 | Blum Robert I President & CEO | Sale 10b5-1 | −5,077 | $53.22 | $270K | 280,967 |
| 2026-11-16 | Blum Robert I President & CEO | Sale 10b5-1 | −2,223 | $54.08 | $120K | 278,744 |
| 2026-11-16 | Blum Robert I President & CEO | Sale 10b5-1 | −200 | $55.21 | $11K | 278,544 |
| 2026-11-16 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 126,745 | ||
| 2026-11-09 | PARSHALL B LYNNE Director | Sale 10b5-1 | −2,445 | $54.17 | $132K | 8,339 |
| 2026-11-09 | PARSHALL B LYNNE Director | Sale 10b5-1 | −2,555 | $55.26 | $141K | 5,784 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $62.93 | $220K | 153,902 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 12,886 | ||
| 2026-11-02 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +7,500 | $10.60 | $80K | 286,044 |
| 2026-11-02 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $62.81 | $471K | 278,544 |
| 2026-11-02 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 134,245 | ||
| 2026-10-20 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-10-20 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $64.01 | $224K | 153,902 |
Page 1 of 45 · 885 trades